Metabolic Effects of Treatment in Patients With Recently Diagnosed Type 2 Diabetes

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00373178

Enrollment

100

Registered

2006-09-07

Start date

2005-01-31

Completion date

2008-06-30

Last updated

2012-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Keywords

rosiglitazone, metformin

Brief summary

The aim of the present study is to investigate the influence of several anti-diabetic regimens (metformin,glitazone,sulfonylurea,glinidine) and diet on metabolic parameters in patients with recently diagnosed type 2 diabetes.

Interventions

DRUGrosiglitazone

DRUGmetformin

DRUGAnti-diabetic medications

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

40 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Recently diagnosed type 2 diabetes * No previous anti-diabetic medications

Exclusion criteria

* Heart failure * Renal disease * Liver disease * Life-threatening diseases

Design outcomes

Primary

Measure	Time frame
Novel cardiovascular risk factors modification	2 years

Secondary

Measure	Time frame
Lipid and glucose regulation	2 years

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026